M
Maria Adelaide Calderazzo
Researcher at National Institutes of Health
Publications - 12
Citations - 466
Maria Adelaide Calderazzo is an academic researcher from National Institutes of Health. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 7, co-authored 10 publications receiving 281 citations. Previous affiliations of Maria Adelaide Calderazzo include Imperial College London.
Papers
More filters
Journal ArticleDOI
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations
Aran Singanayagam,Nicholas Glanville,Jason Girkin,Yee Man Ching,Andrea Marcellini,James D. Porter,Marie Toussaint,Ross P. Walton,Lydia J. Finney,Julia Aniscenko,Jie Zhu,Maria-Belen Trujillo-Torralbo,Maria Adelaide Calderazzo,Christopher Grainge,Su-Ling Loo,Punnam Chander Veerati,Prabuddha S. Pathinayake,Kristy Nichol,Andrew T. Reid,Phillip James,Roberto Solari,Peter A. B. Wark,Darryl A. Knight,Miriam F. Moffatt,William O.C.M. Cookson,Michael R. Edwards,Patrick Mallia,Nathan W. Bartlett,Nathan W. Bartlett,Sebastian L. Johnston +29 more
TL;DR: It is shown that corticosteroid use impairs innate and adaptive immunity to rhinovirus infection, which is restored by exogenous IFNβ, which raises suggestion that inhaled interferon-β therapy may protect.
Journal ArticleDOI
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.
Lydia J. Finney,Nicholas Glanville,Hugo Farne,Julia Aniscenko,Peter Fenwick,Samuel V. Kemp,Maria Belen Trujillo-Torralbo,Su Ling Loo,Maria Adelaide Calderazzo,Jadwiga A. Wedzicha,Patrick Mallia,Nathan W. Bartlett,Sebastian L. Johnston,Aran Singanayagam +13 more
TL;DR: ICS therapies in COPD reduce expression of the SARS-CoV-2 entry receptor ACE2, which may contribute to altered susceptibility to COVID-19 in patients with COPD.
Journal ArticleDOI
Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease
Aran Singanayagam,Nicholas Glanville,Leah Cuthbertson,Nathan W. Bartlett,Nathan W. Bartlett,Lydia J. Finney,Elena M. Turek,Eteri Bakhsoliani,Maria Adelaide Calderazzo,Maria-Belen Trujillo-Torralbo,Joseph Footitt,Phillip James,Peter Fenwick,Samuel V. Kemp,Thomas B. Clarke,Jadwiga A. Wedzicha,Michael R. Edwards,Miriam F. Moffatt,William O.C.M. Cookson,Patrick Mallia,Sebastian L. Johnston +20 more
TL;DR: It is shown that ICS use is associated with lung microbiota disruption leading to proliferation of streptococcal genera, an effect that could be recapitulated in ICS-treated mice, and a central role for cathepsin D/cathelicidin in the suppression of antibacterial host defense by ICS in COPD.
Journal ArticleDOI
Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease.
Patrick Mallia,Patrick Mallia,Jessica Webber,Simren K. Gill,Maria-Belen Trujillo-Torralbo,Maria Adelaide Calderazzo,Lydia J. Finney,Eteri Bakhsoliani,Hugo Farne,Aran Singanayagam,Aran Singanayagam,Joseph Footitt,Richard J. Hewitt,Tatiana Kebadze,Julia Aniscenko,Vijay Padmanaban,Philip L. Molyneaux,Ian M. Adcock,Peter J. Barnes,K Ito,Sarah L. Elkin,Sarah L. Elkin,Onn Min Kon,Onn Min Kon,William O.C.M. Cookson,Miriam F Moffat,Sebastian L. Johnston,Sebastian L. Johnston,John S. Tregoning +28 more
TL;DR: Airway glucose concentrations are increased in patients with stable COPD and further increased during COPD exacerbations, which has important implications for the development of nonantibiotic therapeutic strategies for the prevention or treatment of bacterial infection in patientswith COPD.
Journal ArticleDOI
Antiviral immunity is impaired in COPD patients with frequent exacerbations.
Aran Singanayagam,Su-Ling Loo,Maria Adelaide Calderazzo,Lydia J. Finney,Maria-Belen Trujillo Torralbo,Eteri Bakhsoliani,Jason Girkin,Punnam Chander Veerati,Prabuddha S. Pathinayake,Kristy Nichol,Andrew T. Reid,Joseph Footitt,Peter A. B. Wark,Peter A. B. Wark,Christopher Grainge,Sebastian L. Johnston,Nathan W. Bartlett,Patrick Mallia +17 more
TL;DR: Data implicate deficient airway innate immunity involving epithelial cells in the increased propensity to exacerbations observed in some patients with COPD, and therapeutic approaches to boost innate antimicrobial immunity in the lung could be a viable strategy for prevention and treatment of frequent exacerbations.